Recent data demonstrate promising activity of the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a third-generation TKI, in both treatment-naïve and osimertinib-relapsed patients with EGFR mutated NSCLC [127]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.